XPRIZE Healthspan Top 10 Finalists — Approach & Mechanism of Actions

News
#1

XprizeLongevityFinalists
XprizeLongevityFinalists1920×1072 333 KB

Here is the shortlist of the XPRIZE $100 Million Healthspan “Top 10” finalists (from the Milestone 2 Awardee Lookbook, Appendix F, attached below), with each team’s approach and its stated mechanism of action.

AgelessRx (Ann Arbor, MI) — A telehealth-delivered combination “longevity medicine” protocol. It stacks rapamycin, low-dose naltrexone, metformin, NAD+, glutathione, sermorelin, and tirzepatide with resistance training and health coaching. Mechanism: hits several aging pathways at once — mTOR inhibition, AMPK activation, NAD+ repletion, oxidative-stress reduction, and growth-hormone-axis signaling — plus a proprietary “Infinite Supplement” blend (alpha-ketoglutarate, quercetin, glucosamine, carnosine, pterostilbene, astaxanthin, curcumin).

Goda Lab (University of Tokyo / NanoTitan / Tohoku University / Tokyo Relife Clinic, Japan) — Engineered extracellular vesicles (EVs) from stem cells or plasma. Its “super homotypic targeting” (SHT) platform reprograms EV surfaces for precise tissue delivery. Mechanism: strengthens EV affinity for cells of origin to deliver regenerative miRNAs and proteins to muscle, neural, and immune tissue; preclinically suppressed p16 and p21 and reduced inflammation, targeting multiple hallmarks of aging simultaneously.

Johns Hopkins–Suninflam (Baltimore, MD & San Francisco, CA) — SIF001, a second-generation monoclonal antibody against Galectin-3 (Gal-3), aimed at subclinical Alzheimer’s/MCI. Mechanism: a dual immune/inflammation-and-aggregation approach — blocks Gal-3-mediated chronic inflammation, inhibits Gal-3 oligomerization to prevent amyloid-beta aggregation, and disrupts monocyte/macrophage activation and regulatory T-cell suppression, targeting a shared upstream driver of age-related inflammatory dysregulation.

Longeveron Inc. (Miami, FL; Nasdaq: LGVN) — Laromestrocel (Lomecel-B), an allogeneic bone-marrow-derived mesenchymal stem cell (MSC) therapy for aging-related frailty and Alzheimer’s. Mechanism: a pleiotropic MSC effect — pro-vascular, immunomodulatory, and tissue-repair actions, plus paracrine anti-inflammatory signaling, neuroinflammation suppression, and mitochondrial transfer to damaged cells; positioned to counter “inflammaging” across multiple conditions at once.

Minicircle (Austin, TX) — A non-viral plasmid (“minicircle”) gene therapy delivering two gene cassettes, follistatin (FST) and klotho (KL), by subcutaneous injection. Mechanism: follistatin inhibits myostatin/activin signaling to build muscle and reduce inflammation; klotho modulates FGF23 signaling for systemic anti-aging and neuroprotection — delivered via a transfection reagent-complexed episomal plasmid to avoid viral-vector cost and complexity.

NYC-Vita (Mount Sinai, New York, NY) — A randomized trial combining low-dose rapamycin, spermidine, and structured HIIT/resistance exercise in adults 50–90, with deep multi-omics phenotyping. Mechanism: rebalances aging macrophages to cut chronic inflammation while targeting metabolic, muscle, and cognitive decline — rapamycin inhibits mTOR and suppresses the SASP; spermidine restores autophagy and reduces aging-driven myelopoiesis; home-based exercise drives tissue repair.

Mitochondrial All Stars (Mighty Therapeutics + University of Washington Nathan Shock Center; Needham, MA & Seattle, WA) — Repurposing elamipretide (SS-31 peptide), described as the first and only FDA-approved mitochondria-targeting peptide, as a healthspan intervention. Mechanism: binds cardiolipin in the inner mitochondrial membrane to stabilize/improve mitochondrial function, with associated benefits to brain and muscle function and reduced inflammation markers.

RETRO-EPIGERNA (Macau University of Science and Technology, China) — The KYN Composite Capsule, combining medicinal/edible Chinese herbs and probiotics, built on a discovery linking a specific tRNA epitranscriptional modification to aging. Mechanism: restores that tRNA modification to improve translational fidelity and proteostasis, mitochondrial function, and immune resilience — framed as a multi-system route to reversing aging.

RPRGAON / PRG S&Tech — Progerinin (Busan, South Korea) — Progerinin, a small molecule developed originally for Hutchinson-Gilford Progeria (HGPS), now aimed at general aging. Mechanism: inhibits the progerin–lamin A interaction to drive selective progerin degradation, restoring nuclear membrane/lamina architecture and reversing markers of cellular senescence and genomic instability (progerin also accumulates in normally aging arteries, muscle, and fat).

TIME TRAVELER — Plant-EVs (TIME TRAVELER Corp., Tokyo, Japan) — Parsley-derived plant extracellular vesicles (P-EVs), taken as a dietary supplement ("exofull FUJI"), screened from 140+ edible plant species. *Mechanism:*selected for anti-inflammatory and anti-senescence properties; a proprietary non-thermal, low-stress extraction (“FROZEN-TT01”) preserves purity and biological activity, intended to mitigate age-related declines in muscle strength and physical function.

A quick pattern across the ten: three broad mechanistic camps dominate — combination pharmacologic/lifestyle protocols targeting mTOR/AMPK/NAD+ (AgelessRx, NYC-Vita), cell- and vesicle-based regenerative therapies (Goda Lab, Longeveron, TIME TRAVELER), and targeted molecular interventions against a specific aging driver (Johns Hopkins–Suninflam’s Gal-3, Progerinin’s progerin, Minicircle’s follistatin/klotho, Mitochondrial All Stars’ cardiolipin, RETRO-EPIGERNA’s tRNA modification).

Full report for free download:

Related Reading:

12 Likes
#2

Grouped by mechanistic families:

xprize_finalists
xprize_finalists1920×1080 172 KB

3 Likes
#3

GPT deeper analysis of the (limited, to various degrees) publicly available data related to the ten money-winners.

Excerpts:

Assessment basis

The ratings below apply to the publicly identifiable semifinal or supporting study, not to the confidential data package reviewed by XPRIZE or the future one-year Finals protocol.

XPRIZE required teams to submit de-identified human data, regulatory documentation, and evidence that they could execute and manufacture for clinical trials. The report also says nine funded teams submitted small randomized trials and one submitted a single-arm open-label study. Much of that underlying evidence has not been released publicly, so an apparently thin public record does not necessarily mean XPRIZE saw equally thin evidence. It does mean outsiders cannot yet reproduce the judging.

Rating scale

Design rating Meaning
5/5 Well-designed randomized, blinded controlled study with credible endpoints and statistical handling
4/5 Sound early-phase RCT, with limitations mainly from size, duration, or exploratory endpoints
3/5 Randomized or controlled, but very small, weakly controlled, or difficult to interpret
2/5 Open-label or materially confounded comparison
1/5 Uncontrolled, opaque, retrospectively registered, or otherwise unable to support causal conclusions

I also assign a public-evidence grade:

  • A: peer-reviewed numerical results with enough information for independent appraisal
  • B: substantial numerical report or preprint, but with important limitations
  • C: partial or sponsor-reported results
  • D: registry and narrative only; no auditable result set

Apples-to-apples overview

Team Finalist intervention Best public human evidence Design Public evidence Directness to Finals strategy
AgelessRx Large drug/supplement/exercise/coaching combination 90-day, three-arm randomized pilot; 26 enrolled, 18 analyzed 2/5 C High
Goda Lab Engineered regenerative extracellular vesicles Japanese three-arm, double-blind intranasal exosome trial; results absent 4/5 D Uncertain
Johns Hopkins–Suninflam Anti-Galectin-3 antibody SIF001 Controlled TB006 Alzheimer trial plus early SIF001 studies 4/5 C Medium
Longeveron Laromestrocel/Lomecel-B mesenchymal stem cells Phase 2b frailty RCT and Phase 2a Alzheimer RCT 5/5 A−/B+ High
Minicircle Follistatin plus Klotho plasmid gene therapy Open-label Follistatin study; uncontrolled FST+KL pilot 1/5 B− Medium
NYC-Vita Rapamycin or lamivudine plus spermidine and exercise Small active-comparator trial; only preliminary fragments disclosed 3/5 D High
Mitochondrial All Stars Elamipretide Open-label semifinal pilot; earlier randomized mechanistic study 2/5 semifinal; 4/5 prior RCT D / A− High
RETRO-EPIGERNA Herbal/probiotic capsule targeting tRNA modification Claimed 12-person double-blind RCT; no public registry or numbers 3/5 nominally D Low–medium
Progerinin Progerin-degrading small molecule Healthy-volunteer Phase 1 and tiny active-controlled progeria trial 4/5 safety; 3/5 efficacy D/C− Low for normal aging
TIME TRAVELER Oral parsley-derived extracellular vesicles Registered 40-person double-blind placebo RCT; no numerical results 4/5 D High

Overall conclusions

Public evidence hierarchy

Strongest

1. Longeveron

It has the only clearly mature, peer-reviewed package with sizable randomized trials, transparent numerical results, confidence intervals, multiplicity procedures and disclosed limitations. Even here, the frailty primary comparison missed at six months and the Alzheimer results remain exploratory.

Credible but incomplete

2. Johns Hopkins–Suninflam

The first-generation antibody produced an interesting responder signal, but the primary endpoint missed, and the finalist candidate is a newer antibody.

3. Mitochondrial All Stars

Elamipretide has a legitimate mechanistic RCT and a large safety record. Durable functional efficacy has not been shown, and the semifinal study was uncontrolled.

Reasonable RCT designs with withheld or unavailable results

4. Goda Lab
5. TIME TRAVELER

Both have identifiable randomized, double-blind, placebo-controlled trials. Their central problem is no public numerical outcome report. Goda also has uncertainty over whether the registered exosomes were the actual engineered finalist product; TIME TRAVELER has excessive co-primary outcomes.

Highly preliminary or confounded

6. AgelessRx

Randomized, but underpowered, high attrition, many endpoints and inseparable drug/behavioral components.

7. NYC-Vita

Randomized active comparison, but no untreated control and only fragmentary preliminary analysis.

8. RETRO-EPIGERNA

Nominally blinded and randomized, but only six per group and no auditable registration or results.

Weak evidence bridge

9. Progerinin

A rational rare-disease drug program, but little evidence that the mechanism will translate from progeria to ordinary aging.

Weakest public clinical case

10. Minicircle

No controlled efficacy evidence, retrospective registration, substantial endpoint multiplicity and commercial use ahead of conventional regulatory validation.

What is still missing across most teams

The most consequential omissions are:

  1. Participant-level or complete group-level results, including denominators and missing data.
  2. Adverse-event tables, especially for rapamycin combinations, gene interventions, antibodies, cells and EVs.
  3. Prespecified statistical analysis plans, including multiplicity correction.
  4. Clear product identity, showing that the semifinal-tested product is the same product intended for the Finals.
  5. Effect sizes in clinically interpretable units, rather than statements that a biomarker “improved.”
  6. Durability, since several interventions were tested for only four to twelve weeks.
  7. Independent replication, which none appears to have for the exact healthspan application.

XPRIZE_First_Ten_Clinical_Trial_Analysis_Revised.pdf (61.3 KB)

And if you’ve got a hankering for parsley extracellular vesicles you can buy the probably equivalent product that Time Traveler is testing now. From Japan. (FAQ implies they ship international.)

1 Like
#4

A press release from the SS-31 group:

NEEDHAM, Mass., Aug. 11, 2026 /PRNewswire/ – Mighty Therapeutics (the “Company” or “Mighty”), a commercial-stage biotechnology company pioneering a new class of medicines that directly target mitochondrial dysfunction in rare and age-related diseases, today announced that a joint research team with the University of Washington (UW), led by David Marcinek, Ph.D., has been named a Milestone 2 Awardee in the $101 million XPRIZE Healthspan competition. The award is premised on data from a pilot study evaluating elamipretide, Mighty’s first-in-class mitochondria-targeted peptide, in older adults. These data will inform the design of a larger, controlled trial and Mighty’s continued research into the role of mitochondrial dysfunction in aging.

“This recognition from XPRIZE Healthspan affirms what we’ve believed since our earliest research: that targeting mitochondrial energetics is one of the most powerful levers we have in medicine,” said David A. Brown, Ph.D, Chief Scientific Officer at Mighty. “Impaired cellular energy production underlies every disease we seek to treat. Whether it presents early in life as a rare genetic condition or emerges decades later as a hallmark of aging, mitochondrial dysfunction is a central driver across pathologies. That view is what led us here, and this study led by Dr. Marcinek and his team is a meaningful step in extending mitochondrial research to advance healthy aging.”

Elamipretide binds to cardiolipin, a lipid essential to mitochondrial structure, to improve mitochondrial structure and function, potentially preserving the cell’s capacity to produce energy. Elamipretide is in late-stage development for rare and age-related conditions, including dry age-related macular degeneration (dry AMD), the leading cause of blindness among older adults.

“Our previous research supports the view that mitochondria are a key link between the molecular drivers of aging and age-related pathology leading to reduced quality of life,” said Marcinek, professor of radiology at the UW School of Medicine and Co-Director of the UW Healthy Aging and Longevity Research Institute. “With these feasibility data in hand, we can now move forward to design a gold standard, randomized, double-blind, placebo-controlled study to test whether targeting mitochondria with elamipretide enhances healthy aging by improving muscle, cognitive, and immune function in older adults.”

As one of the 10 Milestone 2 Awardees selected to receive a $1 million award, the Mighty and UW team are advancing into the final phase of XPRIZE Healthspan. That phase requires finalist teams to test their intervention in a rigorous, placebo-controlled clinical trial running through 2029. The competition will culminate in 2030, when the XPRIZE Healthspan judging panel may award up to $81 million to the team(s) whose intervention successfully improves muscle, cognitive and immune function in older adults.

About Mighty Therapeutics

Mighty Therapeutics, together with its wholly owned operating subsidiary, Stealth BioTherapeutics, Inc., is advancing novel therapies for people living with diseases involving mitochondrial dysfunction. Grounded in rigorous science and inspired by meaningful patient partnerships, the company is building a proprietary pipeline to directly address bioenergetic deficits at the source.

1 Like
#5

A new interview with Jamie Justice of XPrize, from yesterday (text):

The Interview

We were curious how the competition had weighed existing scientific evidence against more practical factors like the ability to run a trial in time for the prize deadline. Perhaps unsurprisingly, the ability to run a trial by a deadline was the base criterion in the semi finals. The judges primarily assessed teams’ abilities to get regulatory approvals, recruit human subjects, and deploy in an accelerated fashion. Beyond that gating criterion, the organisers aimed to ensure a balance of innovation, approach, evidence, accessibility and scalability.

As longevity therapeutics should be affordable for all, we asked first how accessibility was prioritised. Dr Justice told us that while some of the Finalists’ therapies may be expensive or hard to get at present, others were not. She cited telemedicine approaches with repurposed and generic drugs or nutraceuticals.

Accessibility is connected to regulatory considerations. While regulations, for instance on gene therapy, can thwart clinical trials in major markets such as the USA (and therefore could limit access during the trial in the USA or cause late availability of a potential intervention even after approvals in other markets), the competition’s uniform and transparent standard meant that wherever in the world they are conducted, trials could be compared head-to-head. The evidence that would emerge was approach-neutral: it could support approaches currently thought either relatively safe or relatively high-risk and high-reward.

This openness to unconventional regulatory approaches should give a therapy an opportunity to get a foothold, scale, then lower its eventual price tag and expand access. However, as we frequently see with other therapies, exclusion from the currently dominant US market can considerably impact pricing. This exclusion is a roadbump to scaling that many biotechs in the past have struggled to overcome.

The trials, she notes, will also generate evidence on real-world practicality – what the therapies cost to deliver, and whether people stick with them – the numbers on which any claim about access ultimately rests. Until then, she suggests, talk of affordability in either direction is speculation. Dr Justice was confident that the Finalist cohort had a diversity of approaches which helped build the evidentiary base on accessibility.

We then got to talk about the data the Finalists were producing:

#6

I found this product interesting because it’s already for sale in Japan (and it is a finalist). So I asked Claude to dig up all the scientific and clinical evidence on this product type. Claude Opus 5 churned away for over an hour on this. Here is what it came back with:

Evidence Assessment: Parsley-Derived Extracellular Vesicles (P-EVs)

Product: exofull FUJI — TIME TRAVELER Corp., Tokyo, Japan

Prepared from a geroscience perspective | 19 August 2026

1. Bottom line

There is no scientific or clinical research that specifically supports any health claim for parsley-derived extracellular vesicles.

This is not a case of weak, mixed, or preliminary evidence. It is a case of absent evidence. A PubMed query for parsley/Petroselinum crispum extracellular vesicles or exosomes returns zero results. No characterization paper, no in vitro study, no animal study, no human study, no toxicology. Three independent plant-EV review articles that between them enumerate 50+ source species do not list parsley among them.

The company’s own claim — “world’s first parsley-derived exosome” (世界初) — is literally accurate and is itself the confirmation: this is a first-in-class material with no published literature behind it.

What exists instead is a three-step inferential chain, none of whose links has been demonstrated for this product:

Link Status
1. The preparation contains genuine extracellular vesicles Unpublished. No TEM/cryo-EM, no size distribution, no marker analysis, no purity data in the public domain
2. Those vesicles survive digestion and are systemically absorbed intact in humans Not demonstrated for any plant EV. No human PK data exist for any orally administered plant EV; the one direct human dietary test of plant small-RNA absorption was negative in serum
3. Systemically delivered plant EV cargo produces a geroprotective effect Contested at the mechanistic level. The cross-kingdom miRNA hypothesis has repeatedly failed independent replication

The defensible reading is that this is a plausible-mechanism, pre-evidence product: the underlying plant-EV field is real and scientifically interesting, but its human evidence base is effectively empty, and parsley specifically has contributed nothing to it.

2. What the product claims

Assembled from the company’s own materials (exofull.com; ttraveler.jp; PR TIMES releases, May and September 2025).

Item Claim
Ingredient “T-GREEN EXOSOME” — parsley-derived exosomes, domestically sourced Japanese parsley
Process “FROZEN–TT01” non-heated / low-temperature extraction over ~80 hours
Dose 2 capsules/day; 60 capsules per bottle (~1 month)
Particle claim 50 billion (500億) “exosomes” per capsule; ~3 trillion (3兆) per bottle (internally consistent)
IP Exclusive license from the University of Tokyo, Institute for Quantitative Biosciences (定量生命科学研究所), Molecular Information laboratory of Prof. Tetsu Akiyama (秋山徹); two patent applications, numbers not disclosed
Health claims “Supports condition maintenance for the aging generation”; “promotes cell repair and regeneration” (細胞の修復と再生を促す); site copy invokes fatigue (疲労), maintenance of concentration and judgment (集中力・判断力の維持), post-exercise recovery, athletic longevity
Price ¥28,000 one-time / ¥22,400 subscription (~US$190/month)
Citations offered None. No publications, no patent numbers, no trial registrations, no in vitro or animal data

Notable disclosure gaps: no mass per dose (only particle count), no particle:protein ratio, no size distribution, no electron microscopy, no marker panel, no residual-solvent or contaminant data, no stability data, no allergen statement, no compositional analysis for parsley’s own hazardous constituents (apiole, myristicin, furanocoumarins).

The company’s stated academic origin is verifiable: Prof. Akiyama is a genuine and well-regarded University of Tokyo cancer and aging biologist. However, his laboratory’s published output is on mammalian cancer stem cells, Mex-3B, SIRT2, and PX-RICS — there are no plant EV or parsley publications from that lab. An institutional affiliation is not evidence for a product.

3. Tier 1 — Evidence on parsley-derived EVs specifically

Zero peer-reviewed publications.

Searched: PubMed, Europe PMC, Google Scholar, bioRxiv, Vesiclepedia/EVpedia, and Japanese-language sources (パセリ エクソソーム / 細胞外小胞), across every plausible term (extracellular vesicle, exosome, exosome-like nanovesicle, nanoparticle, apoplastic vesicle).

Confirmed by triangulation against three independent species censuses in review articles:

  • Int J Nanomedicine plant-ELN review — 29 species enumerated, parsley absent
  • Zhao B et al., Theranostics 2024;14(12):4598–4621 — ~50 species enumerated, parsley absent
  • Front Bioeng Biotechnol 2026 plant EV review — 26 species enumerated, parsley absent

Notably, the family Apiaceae is not unstudied — celery (Apium graveolens) EV work exists, including a 2025 Mol Biol Rep characterization and proteomic analysis of celery root vesicles. The isolation methods have been applied to a close relative. Parsley has simply never been published.

Patents

No parsley-exosome patent could be located in Google Patents (English or Japanese) under University of Tokyo, Akiyama, or TIME TRAVELER. Two candidate documents were checked and excluded: JP7274712B2 (Exostemtech, Korea — general plant exosome mass production, aloe/garlic/seaweed data) and WO2024005199A1 (ISM Co., fish-derived exosomes). The two applications the company references are most likely still pre-publication (Japanese applications publish at 18 months). Their claims and supporting data are therefore unverifiable. A manual J-PlatPat / Espacenet search is the only remaining route.

Interpretation: a pending patent application is a legal filing, not peer review. It establishes a priority claim, not efficacy — and, unexamined and unpublished, it establishes nothing publicly at all.

Preclinical evidence relevant to the specific claims made (“cell repair and regeneration,” fatigue, aging)

The strongest studies in the field — none involving parsley:

Oral, in vivo, functional endpoint (the best available): Qi W, Yang L, Pan Y, et al. Chinese leek-derived extracellular vesicles ameliorate sarcopenia by regulating mitochondrial biogenesis and autophagy via AMPK and maintaining myosin homeostasis. J Nanobiotechnology. 2025;23:721. DOI 10.1186/s12951-025-03764-6. Oral gavage, 25–75 mg/kg, dexamethasone-induced sarcopenia in C57BL/6 mice. Muscle mass and grip strength improved dose-dependently; p-AMPK/AMPK, SIRT1, PGC-1α restored; autophagic flux increased; Pax7⁺ satellite cell pool expanded. Limitations: male mice only; glucocorticoid atrophy is not age-related sarcopenia; no aged cohort; single study, no replication; dosed by protein mass, not particle number; no vesicle-disrupted control to show the vesicle rather than co-purified small molecules did the work.

Senescence — in vitro only: Cho EG, Choi SY, Kim H, et al. Panax ginseng-derived extracellular vesicles facilitate anti-senescence effects in human skin cells. Cells. 2021;10(3):486. Replicatively senescent human dermal fibroblasts: SA-β-gal dose-dependently decreased; p53, p21, p16, MMP1 and IL-8 (SASP) downregulated. The cleanest senescence dataset in plant EVs — but pure cell culture at supraphysiological local concentrations, no in vivo work, no demonstration anything survives a gut, and it is a cosmetics-industry paper.

Same pathway, but injected, and the primary endpoint failed: Zhou X, Xu S, Zhang Z, et al. *J Nanobiotechnology.*2024;22:563 — goji (Lycium barbarum) nanovesicles, AMPK/SIRT1/PGC1α. Intramuscular injection, not oral. Grip strength and fiber CSA improved, but quadriceps muscle weight was not different; fluorescence stayed confined to the injected muscle. The authors themselves note that IM injection bypasses first-pass metabolism and has limited translational relevance to oral consumption, and that they never compared against parent goji extract.

Lifespan: no published study shows plant-derived EVs extend lifespan in C. elegans, Drosophila, or mice. A Lycium ruthenicum ELN paper in transgenic C. elegans (PMID 39922347) acts via DAF-16/FOXO but is an Aβ-proteotoxicity paralysis model, not a lifespan study — it is sometimes misrepresented as such.

The attribution problem runs through all of it. Plant EV preparations co-isolate polyphenols, lipids, proteins, and plant RNA. Almost no study includes the decisive control — a vesicle-disrupted or vesicle-depleted preparation matched for small-molecule content. The convergence on AMPK/SIRT1/PGC-1α is interesting, but that is the pathway hit by essentially every polyphenol and by caloric restriction, which is precisely the alternative explanation.

Summary judgment

The plant-EV field is scientifically legitimate and early. Its best-supported claim is a gut-local one: edible plant exosome-like nanoparticles appear to reach the colon in rodents, are taken up by intestinal epithelium and macrophages, and can modulate gut bacteria. That is a real and interesting finding. It is also a long way from an anti-aging supplement, and it is entirely rodent and in vitro.

exofull FUJI sits at the far end of a chain of extrapolation:

from ginger and grape EVs → to parsley EVs (never published) → from gut-local effects → to systemiceffects (never demonstrated in humans, and directly contradicted by the one human test) → from particle counts → to dose (a category error) → from institutional affiliation → to efficacy (not evidence).

No health claim made for this product is supported by scientific or clinical research on the product, on parsley-derived extracellular vesicles, or on orally administered plant extracellular vesicles in humans. The mechanistic hypothesis is not absurd, and the source material is a common food, so the acute risk is probably low — but “probably low risk” is a statement about parsley, not about an uncharacterized concentrated isolate whose compositional safety has never been published, sold for ~US$190/month for indefinite daily use to an older population.

For a geroscientist, the honest characterization is: a first-in-class material at the pre-characterization stage, marketed as a finished consumer product at a premium price, with an evidence base of zero.

References

Product and company sources

2 Likes
#7

Anyone going to try this?

#8

Some people are already using Spermidine.

#9

I noticed that too. With a potential 6 year increase in healthspan? (see table below).
More generally i do like the diversity - across the Size of Potential Impact vs DIYability trade off.

I asked Grok to estimate the potential Healthspan impact of these in years with interesting results:

Intervention Optimistic Human Healthspan Gain Base-Case Estimate Primary Domains of Impact Evidence Maturity for Aging Path / Timeline Notes
AgelessRX (multi-drug combo) 5–10 years 2–5 years Muscle, metabolic, immune, modest cognitive High real-world use (>100k patients); small RCT Already accessible via telehealth; fastest path
Goda Lab (SHT Super Exosomes) 8–15 years 4–8 years Multi-system (muscle + cognition + immune + tissue) Strong mouse data (~15-yr scaled claim); early clin. New biologic; 5–10+ years to broader use
Johns Hopkins-Suninflam (SIF001 mAb) 5–10 years 2–5 years Immune/inflammation, cognitive (AD-related) Prior AD trial cognitive signals; Phase 1 safety Antibody; moderate timeline if expanded
Longeveron (laromestrocel MSCs) 6–12 years 3–6 years Muscle (frailty), cognitive (mild AD), immune Published Phase 2 RCTs in frailty & mild AD Public company; existing commercial foothold
Minicircle (FST + KL gene therapy) 6–12 years 2–6 years Muscle (follistatin), systemic (klotho), cognitive Pilot human data (lean mass, fat, epigenetic age) Gene therapy; regulatory & delivery hurdles
NYC-Vita (rapamycin + spermidine + exercise) 4–8 years 2–5 years Muscle, immune (inflammaging), modest cognitive Semi-Finals signals + strong component evidence Highly accessible; near-term
Mitochondrial All Stars (Elamipretide) 3–7 years 1–4 years Muscle/energetics primary; secondary cardiac Extensive safety database; single-dose ATP + pilot Approved molecule; faster for muscle focus
RETRO-EPIGERNA (tRNA + herbs capsule) 3–6 years 1–3 years Muscle, immune; modest systemic Small positive RCT (n=12) on muscle/immune Oral capsule; relatively accessible if validated
RPRGAON / Progerinin 5–10 years 2–5 years Cellular senescence, nuclear integrity, muscle/skin Phase 1 + topical skin data; HGPS trial ongoing Small molecule; expanding from rare disease
TIME TRAVELER (Plant-EVs) 3–6 years 1–3 years Muscle strength/performance primary Positive RCT (n=40) in pre-frail adults; commercial Supplement form; fastest consumer path
1 Like
#10

It is hard to past the thresholds in their tests.

#11

Depressing. Think of how many decades we’ve been at the “beat cancer” project. The immense resources that have gone into it, the human talent from all over the world, the massive institutional support. And look at the modest results - cancer is still the #2 killer, millions die and more millions get sick every year. We are so very far from defeating this one class of disease.

Now look at the comically tiny effort in Life Extension compared to the War On Cancer. And life extension in some ways is a more complicated endeavor, even purely conceptually. We certainly don’t even have a clear grasp of what aging is compared to our understanding of what cancer is biologically speaking.

And look at the breadth of effort in this here competition XPRIZE.

If we are brutally honest with ourselves, invoking Churchill’s quote regarding WWII, in the war against aging, we are not even at the beginning of the beginning. We are in medical terms in medieval times, at the “four humours” stage of medicine. At this pace it’s not a question of decades, but centuries. I know biohackers babble on delusionally about escape velocities, but it’s such an easy bet that it won’t happen within anyone’s lifetime of those who are alive today, including those just being born as I type this.

We are no better off today than Ponce de Leon was back in the day, with the same chance of success - essentially cold hard zero. He’s long since been dead as dead can be, and so will be everyone alive today and into the foreseeable future. There is no escape velocity except in third rate science fiction.

Right now we are left with trying to eke out tiny improvements in healthspan with a large dose of blind luck.

Meanwhile $1 million will be awarded to some team or another, with duckall consequence to anyone else.

Of course I wish them well - how could I not, but honestly it’s like watching the search for the philosophical stone at this point in time. Depressing, tragic and shocking. And now I’m going to go give my cat a hug. We ain’t coming out of this alive, not even for a tiny bit longer. YMMV.

3 Likes
#12

That’s a bit of an over the top comment. There is more interest than ever in longevity and we have more tools available than ever to pursue it.

1 Like
#13

My view is different. I have studied this in some detail for few years and I think I understand what the mechanism of ageing and development is and I am doing biohacking experiments to intervene. My team of advisors were unwilling to sign the competitors agreement for Xprize (that was a unanimous decision including me). Otherwise I think Xprize healthspan has its merits.

Winning Xprize at any level is a real challenge.

#14

So it doesnt make any sense they are finalist…
How is that possible ? The company that showed tm5614 reversed horvath was not selected instead of them ? :face_with_peeking_eye:

#15

I have to believe that there is a lot of good private data that they have shared with the XPrize people, that we don’t have access to.

2 Likes
#16

My view is that a lot of the regulatory processes in the world make doing clinical tests that will move the needle really hard (REC -UK IRB -USA). I think to move the needle relatively high doses of interventions are needed and in combinations which are going to be a struggle - even though i have used some of them for about 4 years now)

#17

I agree, it’s a complex problem requiring even more complex solutions.

There is no silver bullet.

Yet we all remain hopeful in improving our individual health spans. Which is much more doable than fully functional and productive life extension, even with 100 as a goal for any significant number of humans.

#18

These 20 Companies are Competing for $101M (XPrize)

I. Executive Summary

The XPRIZE Healthspan competition—a $101 million global initiative—seeks to fundamentally redefine modern medicine by incentivizing interventions that reverse biological aging by 10 to 20 years across three functional domains: cognition, immunity, and muscle function. The core thesis driving this initiative is that biological aging is not an inevitable physiological decay but a programmable, coordinated decline in cellular coherence that can be systematically targeted and reversed. Traditional biopharma paradigms prioritize mono-therapeutic approaches to isolated chronic diseases, such as cardiovascular disease or Alzheimer’s, which often yield only incremental increases in lifespan without extending healthspan. In contrast, the XPRIZE framework mandates multimodal or pleiotropic interventions capable of arresting upstream drivers of senescence, such as mitochondrial dysfunction, immune dysregulation, cellular senescence, and stem cell exhaustion.

The competition’s top 20 finalists reflect a critical pivot from single-pathway hypotheses to combinatorial and AI-driven precision medicine. Key therapeutic modalities include plasmid-based gene therapies targeting muscle-preserving and longevity-associated proteins (Follistatin, Klotho), cellular therapies utilizing mesenchymal stem cells (Lomecel-B) for tissue regeneration, and advanced biologics employing engineered or plant-derived extracellular vesicles to deliver highly targeted molecular payloads. Concurrently, repurposed pharmaceutical stacks—integrating mTOR inhibitors (rapamycin), GLP-1 receptor agonists, and metabolic modulators (metformin, NAD+ precursors)—are being dynamically adjusted via autonomous AI “digital twin” models. This computational approach attempts to overcome the adherence barriers and heterogeneous biological responses typical of static drug regimens.

While the aspiration to restore human function by two decades within a rapid five-year clinical horizon pushes the boundary of current translational science, it forces a necessary aggregation of previously siloed anti-aging research. Clinical implementation, however, remains severely constrained by regulatory bottlenecks, complex manufacturing scaling, and a critical lack of longitudinal Phase 3 human data for novel biologics. The prevailing scientific consensus among investigators is that no single monotherapy will achieve the 20-year functional reversal; sustained success will rely exclusively on precise, personalized multimodal combinations. Consequently, the immediate translational value lies in aggressive drug repurposing and biomarker-driven lifestyle optimization, while isolated gene and cellular therapies remain highly experimental despite robust preclinical signals.

II. Insight Bullets

  • Multimodal Biological Reversal: Achieving a 20-year reduction in biological age requires simultaneous intervention across muscle, immune, and cognitive systems; monotherapies are mathematically and physiologically insufficient for this target.
  • Plasmid-Based Gene Therapy (Mini Circle): Utilizing circular bacterial DNA to transiently encode Follistatin and Klotho offers a scalable, non-integrating, and cost-effective alternative to permanent AAV (adeno-associated virus) vectors.
  • Offshore Regulatory Arbitrage: Novel gene and cellular therapies are predominantly tested in offshore jurisdictions (e.g., Honduras, Bahamas) or under state-specific “Right to Try” laws due to the prohibitive cost and regulatory friction of FDA Phase 1/2 trial structures.
  • Mesenchymal Stem Cells (Longeveron / Lomecel-B): Cellular therapies have advanced to Phase 2 clinical trials, demonstrating measurable improvements in 6-minute walk distances for aging frailty and reduced rates of brain atrophy in Alzheimer’s models.
  • Galectin-3 Inhibition: Emerging as a highly targeted mechanism to suppress neuroinflammation and fibrosis by modulating TREM2 signaling in microglial cells, providing a novel pharmacological vector against cognitive decline.
  • Engineered Extracellular Vesicles (Goda Lab): “Super homotypic” extracellular vesicles are being bioengineered to deliver specific molecular payloads directly to targeted organs, mimicking the body’s endogenous intercellular communication networks.
  • Plant-Derived Biologics (Time Traveler): AI-screened analysis of over 140 Japanese food categories identified parsley-derived extracellular vesicles as potent anti-aging biologics, demonstrating the translational potential of cross-kingdom cellular signaling.
  • Mitochondrial Targeted Peptides (Miti Therapeutics): Synthetic peptides (e.g., Elamipretide) specifically localize to the inner mitochondrial membrane to stabilize cardiolipin, restoring cellular bioenergetics and ATP production in aged and dysfunctional tissues.
  • Macrophage Theory of Aging (NYC Vita): Posits that systemic senescence is primarily driven by hyperactive, dysregulated macrophages that overreact to tissue decay, necessitating early and aggressive inflammatory dampening.
  • Targeted mTOR Inhibition (Rapamycin): Low-dose rapamycin remains the most biologically validated pharmacological intervention for modulating senescence and reducing systemic inflammation, despite historical clinical skepticism over immunosuppression.
  • Combination Drug Repurposing (Ageless RX): Telehealth protocols are stacking GLP-1 receptor agonists, low-dose naltrexone, NAD+ precursors, and rapamycin to aggressively and concurrently target intersecting metabolic and inflammatory pathways.
  • Micro-dosing GLP-1 Agonists: Beyond basic weight loss, micro-dosed GLP-1 receptor agonists (e.g., Tirzepatide, Semaglutide) demonstrate potent secondary effects in reducing systemic inflammation, minimizing “food noise,” and disrupting generalized addictive behaviors.
  • Low-Dose Tadalafil (Cialis): Clinicians are utilizing daily, low-dose PDE5 inhibitors to enhance microvascular circulation and reduce blood pressure, theoretically lowering the incidence rate of vascular dementia.
  • Progerin-Targeted Small Molecules (Team Pragma): Utilizing molecular insights from accelerated aging diseases (Progeria) to identify and target aberrant protein degradation pathways applicable to normal human senescence.
  • Digital Twins for N-of-1 Trials (Ani Biome): Utilizing autonomous AI engines to run in silico human trials generates real-time, highly personalized feedback loops that optimize multi-therapeutic regimens for individual biological variations.
  • Behavioral Neuro-coding: Addressing the critical failure point of patient non-adherence by applying gaming mechanisms to incentivize long-term behavioral compliance with intensive longevity protocols.
  • Spermidine and Autophagy: Clinically utilized to induce autophagy, the cellular process responsible for degrading and recycling damaged organelles and misfolded proteins associated with age-related decline.
  • Metformin Skepticism: While highly effective as a metabolic disease preventative in diabetic cohorts, leading researchers increasingly doubt metformin’s capacity to induce the profound biological restoration required for a 10-20 year age reversal in healthy individuals.
  • Dual Targeting Philosophy: The prevailing commercial strategy requires interventions that not only act on pleiotropic aging pathways but also demonstrate acute efficacy against specific diseases (e.g., Alzheimer’s) to survive pharmaceutical funding cycles.
  • The Ship of Theseus Paradigm: Biological aging necessitates a modular approach; replacing or upgrading individual biological systems (immune, muscular, mitochondrial) incrementally to sustain total systemic coherence.
  • Synergistic Mismatches: Standard clinical trial protocols often fail to capture the exponential, or occasionally antagonistic, effects of combining novel biologics with traditional repurposed pharmaceuticals.
  • The Translation “Valley of Death”: Purely academic consortiums often lack the commercial infrastructure and centralized resources to run robust human trials, placing them at a severe disadvantage compared to capitalized, vertically integrated telehealth platforms.

IV. Actionable Protocol (Prioritized)

High Confidence Tier (Level A/B Evidence)

Experimental Tier (Level C/D Evidence with High Safety Margins)

Red Flag Zone (Safety Data Absent or Elevated Risk)

  • Plasmid-Based Follistatin/Klotho Gene Therapy: While animal models (e.g., CMV vectors) show significant median lifespan extension in mice (Source: MDPI / PMC7209997), systemic human administration in offshore clinics lacks rigorous, peer-reviewed Phase 3 safety and efficacy data. Safety Data Absent.
  • Plant-Derived Extracellular Vesicles: Preclinical data supports the antioxidant and anti-inflammatory roles of plant-derived flavonoids and vesicles (The Role of Antioxidants in the Interplay between Oxidative Stress and Senescence), but isolated systemic administration in humans for biological age reversal is entirely unproven. Safety Data Absent.
  • Unregulated Stem Cell Tourism: The efficacy of stem cell infusions outside of highly controlled clinical parameters is highly variable, carrying inherent risks of tumorigenesis, immunogenic reactions, and severe infections.

Produced by Google Gemini 1.5 Pro

1 Like
#19
1 Like
#20
1 Like